Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback